Marcelo Bravo, Chief Executive Officer discusses their unaudited interim results for the six months to 30 June 2016. Highlights include the substantial progress being made in commercialisation discussions regarding the Company's lead NSAID1 assets, OXPzeroTM Ibuprofen and OXPzeroTM Naproxen.
